Showing results (661-670 of 682) with videos related to

Sort By:
Pageof 69
Blood|December 4, 2015
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatmentPaul G Richardson, Vânia T M Hungria, Sung-Soo Yoon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2009
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathyPaul G Richardson, Wanling Xie, Constantine Mitsiades, et al.
British Journal of Haematology|June 28, 2017
Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trialJesús F San-Miguel, Vania T M Hungria, Sung-Soo Yoon, et al.
British Journal of Haematology|May 10, 2018
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myelomaElizabeth K O'Donnell, Jacob P Laubach, Andrew J Yee, et al.
Blood|May 21, 2011
Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trialAndrzej J Jakubowiak, Kent A Griffith, Donna E Reece, et al.
Blood|July 15, 2006
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaPaul G Richardson, Emily Blood, Constantine S Mitsiades, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2018
A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple MyelomaJacob P Laubach, Chia-Jen Liu, Noopur S Raje, et al.
Blood|January 17, 2014
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaPaul G Richardson, Wanling Xie, Sundar Jagannath, et al.
American Journal of Hematology|August 29, 2019
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myelomaIrene M Ghobrial, Chia-Jen Liu, Oksana Zavidij, et al.
Blood Advances|December 3, 2024
Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myelomaAndrew J Yee, Jacob P Laubach, Erica L Campagnaro, et al.
Pageof 69